Catherine C. Coombs
Hematology | Oncology
101 The City Drive South
Building 23
Orange, CA 92868
Building 23
Orange, CA 92868
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 90 publications
Clonal hematopoiesis in breast cancer: moving beyond prevalence toward clinical relevance.
Journal: Chinese clinical oncology
Published: February 20, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Journal: Current medical research and opinion
Published: January 30, 2026
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 07, 2025
Treatment Decision-Making for Individuals with Relapsed/Refractory Chronic Lymphocytic Leukemia in the USA.
Journal: Acta haematologica
Published: November 25, 2025
BETting on the future: BET inhibition for patients with lymphoma.
Journal: Med (New York, N.Y.)
Published: November 01, 2025
Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.
Journal: Blood cancer journal
Published: October 30, 2025
Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Journal: Future oncology (London, England)
Published: October 03, 2025
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.
Journal: Journal of geriatric oncology
Published: September 26, 2025
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
Journal: Cancer
Published: September 24, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 29, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 27, 2025
Last Updated: 09/26/2026